Key Takeaways
- • Orrick ranked No. 3 globally for venture capital transactions in Q1 2026, according to PitchBook's rankings, while maintaining its No. 1 position in Europe for the tenth consecutive year.
- • The firm advised clients in raising over $40 billion in venture capital financing during Q1 2026, demonstrating significant deal flow across its global platform.
- • Orrick achieved No. 1 global ranking for healthcare services and systems transactions in Q1 2026, reflecting its specialized strength in life sciences and healthtech sectors.
- • The firm ranked No. 4 in the United States for venture capital deal work, positioning it among the top legal advisors across major markets.
- • Orrick's decade-long leadership in European venture capital is reinforced by analysis of over 400 venture capital and growth equity investments completed by its clients across Europe in 2025.
Summary
Orrick maintained its position as a top-tier venture capital legal advisor globally in Q1 2026, securing the No. 3 ranking for venture capital transactions according to PitchBook's league tables. The firm facilitated over $40 billion in venture capital financing during the quarter, underscoring the scale and reach of its global platform across multiple investment stages and geographies.
The firm's European dominance remains particularly pronounced. Orrick extended its decade-long tenure as the No. 1 legal advisor to the European venture capital ecosystem, a distinction the firm has held for ten consecutive years. This leadership position reflects substantial deal flow and client confidence across Europe's venture markets, supported by Orrick's comprehensive regional capabilities spanning multiple countries including Germany and Italy.
Beyond its headline global ranking, Orrick achieved specialized leadership in the healthcare sector, ranking No. 1 globally for healthcare services and systems transactions in Q1 2026. This reflects the firm's focused expertise in life sciences and healthtech, sectors that represent significant growth opportunities within venture capital. The firm's No. 4 ranking in the United States for venture capital deal work demonstrates balanced strength across major markets, though Europe remains its primary competitive advantage.
The rankings are grounded in Orrick's analysis of substantial transaction volume. The firm's Deal Flow 6.0 European Venture Capital Deal Term Review examined more than 400 venture capital and growth equity investments completed by Orrick clients across Europe in 2025, providing empirical support for its leadership claims in the region.
The firm's European dominance remains particularly pronounced. Orrick extended its decade-long tenure as the No. 1 legal advisor to the European venture capital ecosystem, a distinction the firm has held for ten consecutive years. This leadership position reflects substantial deal flow and client confidence across Europe's venture markets, supported by Orrick's comprehensive regional capabilities spanning multiple countries including Germany and Italy.
Beyond its headline global ranking, Orrick achieved specialized leadership in the healthcare sector, ranking No. 1 globally for healthcare services and systems transactions in Q1 2026. This reflects the firm's focused expertise in life sciences and healthtech, sectors that represent significant growth opportunities within venture capital. The firm's No. 4 ranking in the United States for venture capital deal work demonstrates balanced strength across major markets, though Europe remains its primary competitive advantage.
The rankings are grounded in Orrick's analysis of substantial transaction volume. The firm's Deal Flow 6.0 European Venture Capital Deal Term Review examined more than 400 venture capital and growth equity investments completed by Orrick clients across Europe in 2025, providing empirical support for its leadership claims in the region.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.